Cosmo Pharmaceuticals announces licence of Lumeblue™ (Methylene Blue MMX) China rights to China Medical System Holdings Ltd.
Cosmo Pharmaceuticals N.V. today announced that it has licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. (“CMS”) (SEHK: 867).
Lumeblue™ is Cosmo’s recently EMA approved drug for the detection of lesions during colonoscopy.